New hope for liver cancer: immunotherapy and radiation before surgery shows promise

NCT ID NCT07075120

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 23 times

Summary

This study tests a new approach for people with borderline resectable liver cancer, especially Native Hawaiian and Pacific Islander communities who are often hit harder by this disease. Participants will receive two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation, followed by surgery to remove the tumor. The goal is to see if this combination is safe and can help more patients become eligible for curative surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Queen's Medical Center

    RECRUITING

    Honolulu, Hawaii, 96813, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Hawai'i Cancer Center

    NOT_YET_RECRUITING

    Honolulu, Hawaii, 96813, United States

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.